Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.

Pigment cell & melanoma research - 1 Sept 2020

Foth Mona, Parkman Gennie, Battistone Benjamin, McMahon Martin

Abstract excerpt

Mutational activation of RAC1 is detected in ~7% of cutaneous melanoma, with the most frequent mutation (RAC1C85T ) encoding for RAC1P29S . RAC1P29S is a fast-cycling GTPase that leads to accumulation of RAC1P29S -GTP, which has potentially pleiotropic regulatory functions in melanoma cell signaling and biology. However, the precise mechanism by which mutationally activated RAC1P29S propagates its pro-tumorigenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cell Line, Tumor
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to p21-Activated Kinases

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to rac1 GTP-Binding Protein

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 32406574
DOI: 10.1111/pcmr.12889
PMCID: PMC13235968

Genes

PI3
RAC1
PAK1
PIK3CB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.PMID 32406574Read ↗

RAC1 and melanoma.Semantic proximity Read ↗

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy ResistanceSemantic proximity Read ↗

Targeting effector pathways in RAC1P29S-driven malignant melanoma.Semantic proximity Read ↗

RAC1 P29S regulates PD-L1 expression in melanoma.Semantic proximity Read ↗

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanomaSemantic proximity Read ↗

Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma.Semantic proximity Read ↗

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibitionSemantic proximity Read ↗

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.Semantic proximity Read ↗

Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.Semantic proximity Read ↗

Targeting Rac and Cdc42 GTPases in CancerSemantic proximity Read ↗

PI3K Functions Downstream of Cdc42 to Drive Cancer phenotypes in a Melanoma Cell Line.Semantic proximity Read ↗

DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1P29S mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.